Melanotan I Guide & Dosage Chart

What is Melanotan I?

Melanotan I — also called afamelanotide — is a synthetic peptide that mimics a natural hormone in your body called alpha-melanocyte-stimulating hormone (α-MSH). Your body uses α-MSH to tell skin cells called melanocytes to make more melanin, the pigment that gives skin its color and acts as a natural sunscreen. Melanotan I is a beefed-up, longer-lasting version of that signal. It is a melanocortin-1 receptor (MC1R) agonist — meaning it locks onto a specific receptor on melanocytes and switches on pigment production.^[3] In research settings, it has been studied as a prescription implant for rare light-sensitivity diseases and, more broadly, for its role in skin pigmentation biology.

How Melanotan I Works

Think of the MC1R receptor on a melanocyte like a light switch, and α-MSH as the finger that flips it. Melanotan I is an engineered version of that finger — it fits the switch even better and stays there longer. When it binds MC1R, the melanocyte ramps up production of a dark pigment called eumelanin.^[3] More eumelanin in the skin means deeper pigmentation and, importantly in some diseases, a physical barrier against damaging UV light. Because Melanotan I is a close structural relative of α-MSH — a hormone researchers have connected to skin pigmentation and inflammatory pathways — it has attracted interest across several areas of dermatology research.^[4]

What the Research Shows

Erythropoietic Protoporphyria (EPP)

The most studied use of afamelanotide is in erythropoietic protoporphyria (EPP), a rare genetic disorder where the body accumulates a chemical called protoporphyrin. In EPP, even brief sun exposure causes severe burning pain — not a sunburn, but a deep, agonizing sensation. Afamelanotide is a prescription drug (trade name Scenesse) specifically approved to help EPP and X-linked protoporphyria patients tolerate more light by building up their skin's pigment before exposure.^[3] The dosing used in clinical trials is reflected in the dosage chart on this page.

Vitiligo

Vitiligo is a condition where the immune system destroys melanocytes, leaving pale, depigmented patches on the skin.^[2] Because Melanotan I stimulates the very cells that vitiligo destroys, researchers have explored it as a tool to help repigment skin — particularly when combined with narrowband UV-B phototherapy. Multiple reviews of vitiligo treatments have listed afamelanotide among the emerging options being investigated.^[1][6] As of the most recent reviews, no single treatment — including afamelanotide — is considered fully satisfactory for vitiligo, and more long-term data are needed.^[1]

Pigmentation Biology and Pharmacokinetics

Early volunteer studies used lower doses to map how the peptide behaves in the body — how fast it's absorbed, how long it lasts, and at what doses it visibly changes skin tone. Those basic pharmacokinetic findings helped shape the dosing seen in later disease trials. See the dosage chart for the specific ranges used in those volunteer studies.

Other Areas of Interest

Because melanocortin receptors are involved in inflammation and sebum production, Melanotan I has also appeared in reviews of potential acne research compounds — specifically as one of several novel agents being investigated in the context of melanocortin receptor biology.^[4] Researchers have also noted that uncontrolled use of Melanotan I outside clinical settings carries risks, including activation of dysplastic (abnormal) moles — a safety concern flagged in dermatology literature.^[5]

What Melanotan I Is Being Studied For

• Photoprotection in EPP and X-linked protoporphyria — reducing pain and skin damage from light exposure^[3]
• Vitiligo repigmentation — restoring color to depigmented patches, often in combination with phototherapy^[1][6]
• Skin pigmentation pharmacokinetics — understanding how melanocortin agonists behave in healthy volunteers
• Acne-related melanocortin pathways — as part of broader research into sebocyte and keratinocyte biology^[4]

How Melanotan I Is Dosed in Research

Doses vary enormously depending on the research context. EPP clinical trials used a slow-release subcutaneous implant at a much higher total dose than early pharmacokinetic volunteer studies, which used small daily amounts over a ten-day window. The specific milligram amounts, frequencies, and durations used across different research protocols are laid out clearly in the dosage chart on this page — and if you want to explore weight-based scaling, use the calculator tool. This page is a research reference only; these doses are not medical recommendations.

Mixing and Storing Melanotan I

In research lab settings, Melanotan I typically arrives as a lyophilized powder — a freeze-dried solid that must be reconstituted (dissolved) before use. The standard approach is to add bacteriostatic water (sterile water with a small amount of benzyl alcohol to slow bacterial growth) slowly along the inside wall of the vial — never directly onto the powder, which can damage the peptide's structure. Swirl gently; never shake. Once reconstituted, the solution should be stored in a refrigerator (around 2–8 °C / 36–46 °F) and used within a few weeks; for longer storage, the unmixed powder should be kept frozen and away from light. Always label vials with the date of reconstitution. These are standard peptide handling practices for research purposes.

Sources

1. Vitiligo: Pathogenesis and New and Emerging Treatments. — International journal of molecular sciences, 2023. PMID 38139134.
2. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. — International journal of molecular sciences, 2023. PMID 36902341.
3. Afamelanotide. — , 2012. PMID 38598652.
4. From pathogenesis of acne vulgaris to anti-acne agents. — Archives of dermatological research, 2019. PMID 30859308.
5. [Undesirable pigmentation]. — Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2015. PMID 26315100.
6. Treatment Advances in Vitiligo: An Updated Review. — Dermatology practical & conceptual, 2025. PMID 40117616.